NasdaqGS - Delayed Quote • USD
AbCellera Biologics Inc. (ABCL)
At close: April 25 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carl L.G. Hansen Ph.D. | CEO, President & Chairperson | 711.47k | 1.85M | 1975 |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer | 642.42k | 510.82k | 1974 |
| Dr. Veronique Lecault Ph.D. | COO & Director | 645.07k | -- | 1985 |
| Mr. Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer | 644.4k | -- | 1970 |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer | 684.81k | -- | 1971 |
| Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting | -- | -- | -- |
| Dr. Ester Falconer Ph.D. | Chief Technology Officer | -- | -- | 1975 |
| Kathleen Reid B.A. | Head of Corporate Communications | -- | -- | -- |
| Graham Craig M.Sc. | Director of Corporate Development | -- | -- | -- |
| Mr. Murray McCutcheon Ph.D. | Senior Vice President of Partnering | -- | -- | -- |
AbCellera Biologics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 586
Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Corporate Governance
AbCellera Biologics Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Feb 23, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 20, 202410-K: Periodic Financial ReportsSee Full Filing
- Nov 28, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 02, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Oct 13, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 07, 2024
AbCellera Biologics Inc. Earnings Call
Related Tickers
NTLA Intellia Therapeutics, Inc.
20.02
-5.43%
DNA Ginkgo Bioworks Holdings, Inc.
0.7777
-8.05%
BEAM Beam Therapeutics Inc.
21.60
-5.01%
ADPT Adaptive Biotechnologies Corporation
2.6100
+0.38%
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
EDIT Editas Medicine, Inc.
5.22
-2.43%
CRBU Caribou Biosciences, Inc.
3.7600
-2.34%
CRSP CRISPR Therapeutics AG
53.73
-3.45%
BLUE bluebird bio, Inc.
0.9125
-1.13%
PRME Prime Medicine, Inc.
4.3000
-8.51%